OPTN/SRTR 2023 Annual Data Report: Intestine

IF 8.2 2区 医学 Q1 SURGERY American Journal of Transplantation Pub Date : 2025-02-01 DOI:10.1016/j.ajt.2025.01.023
Simon P. Horslen , Vikram K. Raghu , Yoon Son Ahn , Jesse Howell , Benjamin Schumacher , Meghan McDermott , Ajay K. Israni , Jon J. Snyder
{"title":"OPTN/SRTR 2023 Annual Data Report: Intestine","authors":"Simon P. Horslen ,&nbsp;Vikram K. Raghu ,&nbsp;Yoon Son Ahn ,&nbsp;Jesse Howell ,&nbsp;Benjamin Schumacher ,&nbsp;Meghan McDermott ,&nbsp;Ajay K. Israni ,&nbsp;Jon J. Snyder","doi":"10.1016/j.ajt.2025.01.023","DOIUrl":null,"url":null,"abstract":"<div><div>Intestine transplant can have significant health and quality-of-life benefits for those who require it. Despite its infrequent use, intestine transplant remains a mainstay of treating those with complications from long-term parenteral nutrition due to intestinal failure, as well as salvage therapy for those with a significant abdominal catastrophe. In 2023, there were 135 candidates added to the intestine transplant waiting list. Those awaiting intestine-without-liver transplant have low mortality on the waiting list, with no reported deaths in 2023. However, 8 patients died awaiting intestine-with-liver transplant, and the estimated 3-year mortality for those listed exceeds 10.0%. A total of 95 intestine transplants were performed in 2023, with only 33 performed in the pediatric age range. However, 18 of 34 recipients of intestine-with-liver transplant were in the pediatric age range. Immunosuppression for intestine transplants most commonly included an induction agent followed by maintenance with a combination of medications that included tacrolimus. In the recipients of intestine-without-liver transplants, 1- and 5-year graft survival were 78.3% and 46.5% in adult and 76.1% and 52.2% in pediatric recipients, respectively. In the recipients of intestine-with-liver transplants, 1- and 5-year graft survival were 57.8% and 45.6% in adult and 81.1% and 60.0% in pediatric recipients, respectively. Acute rejection episodes occurred for approximately 20.0% of patients within the first year. The 5-year cumulative incidence of posttransplant lymphoproliferative disorder was higher in those with an intestine-without-liver transplant (11.5%) compared with those who also received a liver (2.5%). Rates of intestine transplant have remained stable for the past several years, with increasing need in the adult population. Future reports may reflect whether children who have avoided intestine transplant with the recent advances in intestinal rehabilitation ultimately require the procedure in adulthood.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages S288-S328"},"PeriodicalIF":8.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1600613525000292","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Intestine transplant can have significant health and quality-of-life benefits for those who require it. Despite its infrequent use, intestine transplant remains a mainstay of treating those with complications from long-term parenteral nutrition due to intestinal failure, as well as salvage therapy for those with a significant abdominal catastrophe. In 2023, there were 135 candidates added to the intestine transplant waiting list. Those awaiting intestine-without-liver transplant have low mortality on the waiting list, with no reported deaths in 2023. However, 8 patients died awaiting intestine-with-liver transplant, and the estimated 3-year mortality for those listed exceeds 10.0%. A total of 95 intestine transplants were performed in 2023, with only 33 performed in the pediatric age range. However, 18 of 34 recipients of intestine-with-liver transplant were in the pediatric age range. Immunosuppression for intestine transplants most commonly included an induction agent followed by maintenance with a combination of medications that included tacrolimus. In the recipients of intestine-without-liver transplants, 1- and 5-year graft survival were 78.3% and 46.5% in adult and 76.1% and 52.2% in pediatric recipients, respectively. In the recipients of intestine-with-liver transplants, 1- and 5-year graft survival were 57.8% and 45.6% in adult and 81.1% and 60.0% in pediatric recipients, respectively. Acute rejection episodes occurred for approximately 20.0% of patients within the first year. The 5-year cumulative incidence of posttransplant lymphoproliferative disorder was higher in those with an intestine-without-liver transplant (11.5%) compared with those who also received a liver (2.5%). Rates of intestine transplant have remained stable for the past several years, with increasing need in the adult population. Future reports may reflect whether children who have avoided intestine transplant with the recent advances in intestinal rehabilitation ultimately require the procedure in adulthood.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
OPTN/SRTR 2023年度数据报告:肠
肠移植对那些需要它的人的健康和生活质量有显著的好处。尽管很少使用,但肠移植仍然是治疗长期肠外营养引起的肠衰竭并发症的主要方法,也是治疗腹部重大灾难患者的补救性治疗方法。2023年,有135名候选者加入了肠移植等待名单。等待无肝肠移植的患者死亡率很低,到2023年没有死亡报告。然而,有8名患者在等待肠肝移植时死亡,这些患者的3年死亡率估计超过10.0%。在2023年,总共进行了95例肠道移植手术,其中只有33例是在儿科年龄段进行的。然而,34名接受肝肠移植的患者中有18名是儿童。肠移植的免疫抑制最常见的包括诱导剂,然后用包括他克莫司在内的联合药物维持。在无肝肠移植受者中,成人受者1年和5年的移植存活率分别为78.3%和46.5%,儿童受者为76.1%和52.2%。在肠肝移植受者中,成人受者1年和5年的移植存活率分别为57.8%和45.6%,儿童受者为81.1%和60.0%。大约20.0%的患者在第一年内发生急性排斥反应。移植后淋巴增生性疾病的5年累积发病率在接受肠-肝移植的患者(11.5%)高于接受肝脏移植的患者(2.5%)。肠移植率在过去几年中一直保持稳定,成人的需求在增加。未来的报告可能会反映出,随着肠道康复的最新进展,避免了肠移植的儿童最终是否需要在成年后进行手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
18.70
自引率
4.50%
发文量
346
审稿时长
26 days
期刊介绍: The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide. The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.
期刊最新文献
Spiroplasma infection complicated by macrophage activation syndrome and fulminant hepatitis in a kidney transplanted patient. Anti-AT1R Autoantibodies in pancreas transplantation Rewriting the rule of alloimmunity: a blueprint for B cell-driven transplant outcomes. Pediatric Cardiac Xenotransplantation: A Cautious Approach as Bridge to Allotransplantation. Occult rat Hepatitis E Virus Infection as a Cause of Cirrhosis and Post-Transplant Recurrence: Insights into the Role of Metagenomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1